Skip to main content

Table 3 EGFR status subgroup analysis of the ALTER0303 trial

From: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

EGFR status Median OS (months) HR (95% CI) P value
Placebo arm Anlotinib arm
Wild-type 6.47 8.87 0.73 (0.55–0.97) 0.022
Sensitive mutationsa 6.27 10.70 0.59 (0.38–0.94) 0.023
  1. EGFR, epidermal growth factor receptor; OS, overall survival; HR, hazard ratio
  2. aSensitive mutations include exon 19 deletion and exon 21 Leu858Arg